Aethlon at Forefront of Broad-Spectrum Virus Treatment With Hemopurifier (From June... RedChip Article)
As the world population continues to grow and distances between people dwindle, a different kind of threat to personal safety, other than bullets, bombs, natural disasters or accidents, is much on the minds of our globally connected population: germs. More specifically, global pandemics of deadly germs.
According to the World Health Organization, nearly 36 thousand people in 76 countries have been infected with the H1N1 virus (Swine flu), causing 163 deaths. As fears that the virus may mutate to a more potent strain mount, the lesson is clear: more people plus more travel equals more germ transmission. While outbreaks of deadly diseases in the past (and present) such as Typhoid fever and influenza are horrific, humankind’s effort and scientific achievements in the name of combating such diseases are truly awe-inspiring.
One such innovator is Aethlon Medical, Inc. (OTC BB: AEMD), developer of the Hemopurifier®. The Hemopurifier is a patented extracorporeal device that captures circulating viruses and viral proteins and toxins before the occurrence of cell and organ infection. The filtration device has already seen significant results in the treatment of HIV, Hepatitus C, Marburg, Ebola, Measles, Mumps, influenza (including the strain of H1N1 that left 57 people dead in the U.S. earlier this year), and Orthopox virus. The Hemopurifier is classified as a broad-spectrum antiretroviral — broad-spectrum inhibitors are naturally occurring antiviral compounds occurring in certain kinds of mushrooms and fungi.
On May 5, 2009, Aethlon reported the following:
“[A]n HIV-infected individual, who received 12 Hemopurifier® treatments during the span of one month, had an average viral load reduction of 55% during each four-hour Hemopurifier® treatment. The study was conducted in the absence of any antiviral drug therapy. Based on this data, mathematical treatment models of approximately 1.5 days of continuous Hemopurifier® treatment would reduce patient viral load to undetectable levels.”
The problem with viral diseases, as anyone who has received a flu shot in the spring knows, is that they are continually evolving. The AIDS and HIV viruses are the most notorious cases of this, and their continually evolving resistance to treatment methods makes them among some of the deadliest in the world. Treatments for such viruses involve multiple-medication “cocktails” taken several times a day, and side effects can include nausea, diarrhea, malaise, and fatigue. Tantamount to finding effective treatments is the goal of finding treatments that improve the patient’s quality of life overall as well as reduce viral load in the bloodstream, as months of treatment can be physically, mentally and emotionally debilitating.
Aethlon’s Hemopurifier is remarkable not only because initial observations from the HIV study indicate the device could inhibit and reverse HIV disease progression in the absence of antiviral drugs but also because the same device may be usable for treating different viral diseases. Since the beginning of 2009, the Hemopurifier® has been demonstrated safe and effective in reducing patient viral load in both Hepatitis-C Virus (HCV) and Human Immunodeficiency Virus (HIV) infections. Aethlon believes the Hemopurifier® is the first therapeutic candidate to demonstrate viral reduction benefit against two different viral species in human studies.
James A. Joyce, Chairman and CEO of Aethlon, in his 2008 publication, The Broad-Spectrum Treatment of Biological Weapons and Emerging Pandemic Threats, writes:
“The advancement of single-target drug and vaccine therapies as the predominant strategy to address a universe of known and unknown bioterror and pandemic threats is clinically and economically unfeasible. Accordingly, the Department of Health and Human Services (HHS) of the United States has decreed that broad-spectrum therapies, able to demonstrate effectiveness in combating multiple pathogens, will become a focal point for government initiatives that encourage the development of countermeasures against bioterror and pandemic threats.”
Rather than focus efforts on combating a single virus, Aethlon’s more modern approach to combating such pandemics seems to be paying off. To date, the data further reinforces the company’s position of the Hemopurifier® as a leading broad-spectrum countermeasure against drug and vaccine resistant viruses. Truly remarkable.
